Indiana University School of Medicine, Riley Hospital for Children-Assistant Professor of Surgery
My lab’s research focus is on identifying novel therapies for the treatment of intestinal ischemia and necrotizing enterocolitis. We are currently looking at two different therapies in an adult model of intestinal ischemia and a mouse model of NEC. These therapies include the use of stem cells as well as the use of hydrogen sulfide donors to promote mesenteric vasodilation and improved intestinal perfusion. Future goals are to understand the mechanisms of these therapies, and to translate them into clinical applications.
Markel TA, Crafts TD, Jensen AR, Hunsberger EB, Yoder MC. Human Mesenchymal Stem Cells Decrease Mortality Following Intestinal Ischemia and Reperfusion Injury. J Surg Res. 2015; 199(1):56-66. PMID:26219205 *
Crafts TD, Hunsberger EB, Jensen AR, Rescorla FJ, Yoder MC, Markel TA. Direct Peritoneal Resuscitation Improves Survival and Decreases Inflammation Following Intestinal Ischemia and Reperfusion Injury. J Surg Res. 2015; 199(2):428-34. PMID: 26169030 *
Jensen AR, Doster DL, Hunsberger EB, Manning MM, Stokes SM, March KL, Yoder MC, Markel TA. Human Adipose Stromal Cells Increase Survival and Mesenteric Perfusion Following Intestinal Ischemia. Shock. 2016; 46(1):75-82. PMID: 26796571 *
Jensen AR, Manning MM, Khaneki S, Drucker NA, Markel TA. Harvest Tissue Source Does Not Alter the Protective Power of Stromal Cell Therapy Following Intestinal Ischemia and Reperfusion Injury. J Surg Res. 2016. In press.*
Doster DL, Jensen AR, Khaneki S, Markel TA. Mesenchymal Stromal Cell Therapy for the Treatment of Intestinal Ischemia: Defining the Optimal Cell Line for Maximum Therapeutic Benefit. Cytotherapy, 2016, In press. *